Although DPP-4 inhibitors do not cross the BBB under normal conditions (the pharmacokinetic feature may prevent their repurposing use in neurodegenerative diseases), the permeability of BBB is increased in neurodegenerative diseases, so molecules otherwise unable to cross BBB could enter into CNS in these conditions (103). Here, DPP4 is linked to neurodegenerative disease.